Mary C. Tanner

Directeur/Membre du Conseil chez PEARL HOLDINGS ACQUISITION CORP

Profil

Mary C.
Tanner is the founder of Evolution Life Science Partners.
She is currently serving as an Independent Director at Pearl Holdings Acquisition Corp.
She previously held positions as an Independent Director at Synvista Therapeutics, Inc. from 2006 to 2009, a Senior Managing Director at Bear, Stearns & Co., Inc. from 2000 to 2004, and a Senior Managing Director at Lehman Brothers, Inc. from 1979 to 1999.
Ms. Tanner has also served as a Director at Block Drug Co., Inc., ARIAD Pharmaceuticals, Inc., HaptoGuard, Inc., Lineagen, Inc., Calliditas Therapeutics Suisse SA, and Pangenx, Inc. .
Additionally, she worked as a Managing Director at Peter J.
Solomon Co. LP from 2009 to 2013, an Independent Director at Calliditas Therapeutics France SAS from 2015 to 2020, and a Member-Supervisory Board at Evotec SE from 2005 to 2014.
Ms. Tanner's education includes an undergraduate degree from Harvard University, which she received in 1973.

Postes actifs de Mary C. Tanner

Sociétés	Poste	Début
PEARL HOLDINGS ACQUISITION CORP	Directeur/Membre du Conseil	01/12/2021
Evolution Life Science Partners	Fondateur	-

Anciens postes connus de Mary C. Tanner

Sociétés	Poste	Fin
GENKYOTEX SA.	Directeur/Membre du Conseil	03/11/2020
EVOTEC SE	Directeur/Membre du Conseil	17/06/2014
Block Drug Co., Inc.	Directeur/Membre du Conseil	19/03/2013
Peter J. Solomon Co. LP	Corporate Officer/Principal	-
SYNVISTA THERAPEUTICS, INC.	Directeur/Membre du Conseil	01/01/2009